Trial: Gedatolisib Plus Fulvestrant With or Wi…

Trial Details

Sponsor: Celcuity Inc (industry)

Phase: 3

Start date: Dec. 8, 2022

Planned enrollment: 701

Trial ID: NCT05501886

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Gedatolisib (PKI-587, PF-05212384)

Overview

Gedatolisib (PF-05212384; PKI‑587) is an investigational, intravenous dual inhibitor of class I PI3K isoforms and mTOR complexes 1/2 being developed primarily for hormone receptor–positive, HER2‑negative (HR+/HER2−) advanced breast cancer and other solid tumors. Early first‑in‑human work established a weekly dosing schedule with a manageable toxicity profile, and subsequent studies have explored combinations with endocrine therapy, CDK4/6 inhibitors, chemotherapy, PARP inhibitors, and other agents. (pubmed.ncbi.nlm.nih.gov)

Mechanism of action

Gedatolisib potently inhibits all four class I PI3K isoforms (p110α/β/γ/δ) and mTORC1/2, aiming to produce comprehensive blockade of PI3K/AKT/mTOR signaling and limit adaptive resistance seen with single‑node inhibitors. Preclinical work in breast cancer models showed greater anti‑proliferative and cytotoxic activity versus alpelisib (PI3Kα), capivasertib (AKT), or everolimus (mTORC1), irrespective of PAM‑pathway mutational status. (pubmed.ncbi.nlm.nih.gov)

Efficacy

First‑in‑human phase I (advanced solid tumors): Preliminary antitumor activity was observed with two confirmed partial responses and one unconfirmed PR; eight patients had stable disease >6 months. (pubmed.ncbi.nlm.nih.gov)
Phase I dose‑escalation with carboplatin/paclitaxel (advanced solid tumors; majority ovarian): ORR 65% overall and 80% in clear cell ovarian cancer; recommended phase II dose established. (pubmed.ncbi.nlm.nih.gov)
Phase 1b expansion in HR+/HER2− metastatic breast cancer (gedatolisib + palbociclib + endocrine therapy): Reported median PFS 12.9 months and ORR 63% after prior CDK4/6 inhibitor plus aromatase inhibitor; activity observed regardless of PIK3CA mutation status. (Abstract data.) (ascopubs.org)
Phase I combinations in breast cancer:
Gedatolisib + cofetuzumab pelidotin (metastatic TNBC/ER‑low): ORR 16.7%, clinical benefit at 18 weeks 27.8%, median PFS 2.0 months. (pubmed.ncbi.nlm.nih.gov)
Gedatolisib + talazoparib (advanced TNBC or BRCA1/2+, HER2−): ORR 12%, median PFS 2.5 months; did not meet prespecified efficacy threshold. (pubmed.ncbi.nlm.nih.gov)
Phase 3 (VIKTORIA‑1) topline, PIK3CA wild‑type cohort (HR+/HER2− ABC after CDK4/6i + AI):
Gedatolisib + palbociclib + fulvestrant: HR for progression or death 0.24 (95% CI 0.17–0.35), median PFS 9.3 vs 2.0 months vs fulvestrant.
Gedatolisib + fulvestrant: HR 0.33 (95% CI 0.24–0.48), median PFS 7.4 vs 2.0 months.
These are company‑reported topline results; full peer‑reviewed data are pending. (celcuity.com)

Ongoing/Planned phase 3: VIKTORIA‑2 (first‑line HR+/HER2− ABC, endocrine‑resistant) is randomizing fulvestrant + investigator’s‑choice CDK4/6 inhibitor with or without gedatolisib; first patient dosed July 24, 2025. (aacrjournals.org)

Safety

Class‑consistent adverse events observed across studies include stomatitis/mucositis, nausea, hyperglycemia, fatigue, decreased appetite, transaminase elevations, and myelosuppression when combined with chemotherapy. In the first‑in‑human study, the most common treatment‑related AEs were stomatitis (58%), nausea (43%), hyperglycemia (26%); grade 3 treatment‑related AEs occurred in 24% at the MTD (154 mg weekly), with no treatment‑related grade 4–5 events. (pubmed.ncbi.nlm.nih.gov)
With carboplatin/paclitaxel, frequent grade ≥3 events included neutropenia (35%), anemia (18%), and mucositis (12%); dose‑limiting toxicities informed the recommended phase II dose. (pubmed.ncbi.nlm.nih.gov)
In early HR+/HER2− breast cancer combinations, abstracted results describe a manageable profile with low discontinuation rates; company‑reported VIKTORIA‑1 topline notes lower discontinuations and lower rates of hyperglycemia and stomatitis versus earlier phase data, pending full disclosure. (ascopubs.org)

Additional notes

Pharmacokinetics: Weekly IV dosing shows biphasic PK with half‑life ~30–37 hours after multiple dosing. (pubmed.ncbi.nlm.nih.gov)
Potential resistance: Overexpression of efflux transporters (ABCB1/ABCG2) has been implicated in reduced cellular efficacy in preclinical models. (pubmed.ncbi.nlm.nih.gov)

HealthScout AI Analysis

Goal: Evaluate whether adding the pan-PI3K/mTOR inhibitor gedatolisib to fulvestrant, with or without palbociclib, improves outcomes versus standard-of-care therapies in HR-positive, HER2-negative advanced breast cancer that has progressed on a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor, with analyses stratified by PIK3CA mutation status.

Patients: Adults with inoperable locally advanced or metastatic HR+/HER2− breast cancer, ECOG 0–1, who experienced radiographic progression on or after a CDK4/6 inhibitor combined with a non-steroidal aromatase inhibitor. Both sexes eligible; pre/peri-menopausal women require LHRH agonist therapy. Adequate organ function is required and evaluable disease per RECIST v1.1 is mandatory; bone-only disease must include lytic or mixed lesions. Key exclusions include prior PI3K/Akt/mTOR inhibitors, chemotherapy or ADCs for advanced disease, >2 prior lines of endocrine therapy, uncontrolled diabetes, active/untreated CNS metastases, and significant recent cardiovascular disease.

Design: Phase 3, open-label, randomized, multi-arm study with allocation by PIK3CA mutation status. Approximately 701 participants will be randomized after central confirmation of PIK3CA status. Efficacy is assessed by blinded independent central review of imaging per RECIST v1.1.

Treatments: For PIK3CA wild-type: Arm A gedatolisib + palbociclib + fulvestrant; Arm B gedatolisib + fulvestrant; Arm C fulvestrant alone (active comparator). For PIK3CA-mutant: Arm D gedatolisib + palbociclib + fulvestrant; Arm F gedatolisib + fulvestrant; Arm E alpelisib + fulvestrant (active comparator). Gedatolisib is an intravenously administered, potent pan-class I PI3K and mTORC1/2 inhibitor targeting the PI3K/AKT/mTOR pathway to overcome resistance to endocrine and CDK4/6 therapies. Early-phase studies in HR+/HER2− disease showed manageable safety and promising activity when combined with palbociclib and endocrine therapy, including objective responses in both treatment-naïve and CDK4/6-pretreated cohorts, with neutropenia largely attributable to palbociclib. Fulvestrant is a SERD standard therapy; palbociclib is a CDK4/6 inhibitor standard-of-care partner; alpelisib is a PI3Kα inhibitor approved with fulvestrant for PIK3CA-mutant disease.

Outcomes: Primary endpoint: progression-free survival by blinded independent central review in both PIK3CA wild-type and mutant cohorts. Key secondary endpoints include overall survival, overall response rate, duration of response, time to response, and clinical benefit rate, all per RECIST v1.1 and BICR. Additional secondary endpoints assess patient-reported outcomes and quality of life (FACT-B TOI, NFBSI-16, PROMIS Physical Function 8c, EQ-5D-5L) and safety/tolerability per NCI CTCAE v5.0.

Burden on patient: Moderate. Participation requires baseline and longitudinal tumor tissue availability for PIK3CA testing, regular clinic visits for IV gedatolisib infusions, and oral administration of palbociclib and/or alpelisib or fulvestrant injections depending on arm. Imaging at regular intervals per RECIST with centralized review, routine laboratory monitoring including glucose and metabolic panels, hematology for CDK4/6-related myelosuppression, and adverse event assessments are expected. Compared with standard-of-care endocrine-based regimens, burden increases due to IV infusions, potential more frequent labs for metabolic and hematologic monitoring, and clinic time for fulvestrant injections; however, there are no intensive pharmacokinetic schedules typical of early-phase trials, and imaging frequency is likely similar to standard practice.

Last updated: Oct 2025

Eligibility

Show Criteria

Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study.

2. Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment

3. Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing an assay consistent with local standards

4. Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance

5. Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status

6. Subject must have documentation of radiological disease progression on or after the last prior treatment and also have radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone only disease must have lytic or mixed lytic/blastic lesions that can be accurately assessed; bone only blastic lesions with no soft tissue component is not allowed.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

8. Life expectancy of at least 3 months

9. Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI)

10. Adequate bone marrow, hepatic, renal and coagulation function

Exclusion Criteria:

1. History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥3 years

2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor

3. Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted)

4. More than 2 lines of prior endocrine therapy treatment

5. Bone only disease that is only blastic with no soft tissue component

6. Subjects with type 1 diabetes or uncontrolled type 2 diabetes

7. Known and untreated, or active, brain or leptomeningeal metastases

a. Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to enrollment

8. Patients with advanced, symptomatic, visceral spread that are at risk of life-threatening complication in the short-term

9. History of clinically significant cardiovascular abnormalities such as: Congestive heart failure (New York Heart Association (NYHA) classification ≥ II within 6 months of study entry

1. Myocardial infarction within 12 months of study entry

2. History of any uncontrolled (or untreated) clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block), supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months

3. Uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication (initiation or adjustment of antihypertensive medication\[s\] is allowed prior to screening)

4. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

* i. Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, or history of clinically significant/symptomatic bradycardia

* ii. On screening, inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not interpretable) or QTcF \>480 msec (determined by mean of triplicate ECGs at screening)

10. Known hypersensitivity to the study drugs or their components

11. Pregnant or breast-feeding women

12. Concurrent participation in another interventional clinical trial

1. Subjects must agree not to participate in another clinical trial (other than observational) at any time during participation in VIKTORIA-1.

Sites (217)

Sort by distance to:

9 of July Sanatorium

San Miguel de Tucumán, Argentina

No email / No phone

Status: Recruiting

Alexander Fleming Institute

Buenos Aires, Argentina

No email / No phone

Status: Recruiting

Buenos Aires British Hospital

Buenos Aires, Argentina

No email / No phone

Status: Recruiting

CEDIT Diagnostic and treatment center

Salta, Argentina

No email / No phone

Status: Recruiting

CENIT Foundation

Buenos Aires, Argentina

No email / No phone

Status: Recruiting

CER San Juan

San Juan, Argentina

No email / No phone

Status: Recruiting

Center for Medical Education and Clinical Research (CEMIC)

Buenos Aires, Argentina

No email / No phone

Status: Recruiting

Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)

Paraná, Argentina

No email / No phone

Status: Recruiting

Cordoba Oncology Institute (IONC)

Córdoba, Argentina

No email / No phone

Status: Recruiting

Fleischer Medical Center

Buenos Aires, Argentina

No email / No phone

Status: Recruiting

Medical Center Austral

Buenos Aires, Argentina

No email / No phone

Status: Recruiting

Rosario's Oncology Institute and Medical Specialities (IOR)

Santa Fe, Argentina

No email / No phone

Status: Recruiting

Adelaide Oncology & Haematology

Adelaide, Australia

No email / No phone

Status: Recruiting

Hollywood Private Hospital, Breast Cancer Research Centre

Nedlands, Australia

No email / No phone

Status: Recruiting

Icon Cancer Centre- Southport

Southport, Australia

No email / No phone

Status: Recruiting

Mater Hospital Brisbane, Mater Cancer Care Centre

South Brisbane, Australia

No email / No phone

Status: Recruiting

St Vincent's Hospital (Melbourne) Ltd

Fitzroy, Australia

No email / No phone

Status: Recruiting

Sydney Adventist Hospital

Wahroonga, Australia

No email / No phone

Status: Recruiting

The Queen Elizabeth Hospital

Woodville, Australia

No email / No phone

Status: Recruiting

Hospital Hietzing, Department of Gynecology

Vienna, Austria

No email / No phone

Status: Recruiting

Medical University Vienna, Department of Gynecology and Obstetrics

Vienna, Austria

No email / No phone

Status: Recruiting

Order Hospital Linz Ltd. - Hospital of Sisters of Mercy, Department of Internal Medicine I

Linz, Austria

No email / No phone

Status: Recruiting

Salzburg Regional Hospital, Department of Internal Medicine III

Salzburg, Austria

No email / No phone

Status: Recruiting

University Hospital Graz, Department of Gynecology and Obstetrics

Graz, Austria

No email / No phone

Status: Recruiting

University Hospital Innsbruck - Tyrolean Hospital, Department of Gynaecology and Obstetrics

Innsbruck, Austria

No email / No phone

Status: Recruiting

University Hospital St. Poelten, Department of Internal Medicine I

Sankt Pölten, Austria

No email / No phone

Status: Recruiting

AZ Groeninge

Kortrijk, Belgium

No email / No phone

Status: Recruiting

Centre Hospitalier Peltzer-la-Tourelle

Verviers, Belgium

No email / No phone

Status: Recruiting

Charleroi Grand Hospital (GHDC)

Charleroi, Belgium

No email / No phone

Status: Recruiting

Citadelle Regional Hospital Center

Liège, Belgium

No email / No phone

Status: Recruiting

Saint Luc University Hospital

Brussels, Belgium

No email / No phone

Status: Recruiting

UCL Mont-Godinne University Hospitals

Yvoir, Belgium

No email / No phone

Status: Recruiting

University Hospital Antwerp (UZA)

Edegem, Belgium

No email / No phone

Status: Recruiting

University Hospitals Leuven, Campus Gasthuisberg

Leuven, Belgium

No email / No phone

Status: Recruiting

VITAZ

Sint-Niklaas, Belgium

No email / No phone

Status: Recruiting

Bahia Oncology Center

Salvador, Brazil

No email / No phone

Status: Recruiting

D'OR Institute

São Paulo, Brazil

No email / No phone

Status: Recruiting

Hospital A.C.Camargo

São Paulo, Brazil

No email / No phone

Status: Recruiting

Juiz de Fora Eurolatino Research Center

Minas Gerais, Brazil

No email / No phone

Status: Recruiting

ONCOSITE - Clinical Research Center in Oncology

Ijuí, Brazil

No email / No phone

Status: Recruiting

Pronutrir

Fortaleza, Brazil

No email / No phone

Status: Recruiting

Oncology Treatment Center

Belém, Pará, Brazil

No email / No phone

Status: Recruiting

MHAT for Women's Health "Nadezhda"

Sofia, Bulgaria

No email / No phone

Status: Recruiting

Multiprofile Hospital for Active Treatment "Serdika", Sofia

Sofia, Bulgaria

No email / No phone

Status: Recruiting

Multiprofile Hospital for Active Treatment - Uni Hospital, Panagyurishte

Panagyurishte, Bulgaria

No email / No phone

Status: Recruiting

Specialized Hospital for Active Treatment in Oncology, Clinic of Medicial Oncology (Chemotherapy)

Sofia, Bulgaria

No email / No phone

Status: Recruiting

University Multiprofile Hospital for Active Treatment "Sveta Marina"

Varna, Bulgaria

No email / No phone

Status: Recruiting

CIUSSS du Saguenay Lac St-Jean

Chicoutimi, Quebec, Canada

No email / No phone

Status: Recruiting

Maisonneuve-Rosemont Hospital

Montreal, Quebec, Canada

No email / No phone

Status: Recruiting

Thomayer University Hospital, Clinic of Oncology

Prague, Czechia

No email / No phone

Status: Recruiting

University Hospital Bulovka, Institute of Radiation Oncology

Prague, Czechia

No email / No phone

Status: Recruiting

University Hospital Motol, Clinic of Oncology

Prague, Czechia

No email / No phone

Status: Recruiting

University Hospital Olomouc, Clinic of Oncology

Olomouc, Czechia

No email / No phone

Status: Recruiting

Bergonie Institute

Bordeaux, France

No email / No phone

Status: Recruiting

CHU La Timone - La Timone Children's Hospital

Marseille, France

No email / No phone

Status: Recruiting

Francois Baclesse Center

Caen, 14076, France

No email / No phone

Status: Recruiting

Gustave Roussy

Villejuif, France

No email / No phone

Status: Recruiting

La Roche-sur-Yon Hospital

La Roche-sur-Yon, 85925, France

No email / No phone

Status: Recruiting

Saint Anne Clinic

Strasbourg, France

No email / No phone

Status: Recruiting

University Hospital Center of Poitiers

Poitiers, France

No email / No phone

Status: Recruiting

Caritas Klinikum

Saarbrücken, Germany

No email / No phone

Status: Recruiting

Helios Clinic Wuppertal

Wuppertal, Germany

No email / No phone

Status: Recruiting

Hospital Bayreuth

Bayreuth, Germany

No email / No phone

Status: Recruiting

Hospital Suedstadt Rostock

Dorf Mecklenburg, Germany

No email / No phone

Status: Recruiting

Private Practice with Focus on Oncology

Lübeck, Germany

No email / No phone

Status: Recruiting

University Hospital Johannes Gutenberg - University of Mainz

Mainz, Germany

No email / No phone

Status: Recruiting

University Hospital Muenster

Münster, Germany

No email / No phone

Status: Recruiting

Vivantes Hospital Am Urban

Berlin, Germany

No email / No phone

Status: Recruiting

Alexandra General Hospital

Athens, Greece

No email / No phone

Status: Recruiting

EUROMEDICA General Clinic of Thessaloniki

Thessaloniki, Greece

No email / No phone

Status: Recruiting

IASO Thessaly SA

Larissa, Greece

No email / No phone

Status: Recruiting

Theageneio Anticancer Hospital of Thessaloniki

Thessaloniki, Greece

No email / No phone

Status: Recruiting

University General Hospital of Ioannina

Ioannina, Greece

No email / No phone

Status: Recruiting

Bacs-Kiskun County Hospital, Center for Oncoradiology

Kecskemét, Hungary

No email / No phone

Status: Recruiting

Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Oncology

Nyíregyháza, Hungary

No email / No phone

Status: Recruiting

University of Debrecen Clinical Center, Institute of Oncology

Debrecen, Hungary

No email / No phone

Status: Recruiting

European Institute of Oncology (IEO), IRCCS

Milan, Italy

No email / No phone

Status: Recruiting

Local Healthcare Company of Monza (ASST Monza)

Monza, Italy

No email / No phone

Status: Recruiting

New Hospital of Prato (NOP)

Prato, Italy

No email / No phone

Status: Recruiting

Santa Maria della Misericordia University Hospital of Udine

Udine, Italy

No email / No phone

Status: Recruiting

University Hospital Campus Bio-Medico

Rome, Italy

No email / No phone

Status: Recruiting

University Hospital of Parma

Parma, Italy

No email / No phone

Status: Recruiting

University Polyclinic Foundation "Agostino Gemelli" - IRCCS

Rome, Italy

No email / No phone

Status: Recruiting

University Polyclinic Hospital of Modena

Modena, Italy

No email / No phone

Status: Recruiting

Administrative Society of Health Services, SC

Morelia, Mexico

No email / No phone

Status: Recruiting

Avix Clinical Research

Nuevo León, Mexico

No email / No phone

Status: Recruiting

CRYPTEX

Mexico City, Mexico

No email / No phone

Status: Recruiting

Clinical Research Center Chapultepec Mexico City

Mexico City, Mexico

No email / No phone

Status: Recruiting

Filios High Medicine

Monterrey, 64460, Mexico

No email / No phone

Status: Recruiting

ONCOR Life Medical Center

Saltillo, Mexico

No email / No phone

Status: Recruiting

ProcliniQ Clinical Research

Mexico City, Mexico

No email / No phone

Status: Recruiting

Zambrano Hellion Medical Center

Nuevo León, Mexico

No email / No phone

Status: Recruiting

Independent Public Healthcare Facility Prof. Tadeusz Koszarowski Opole Oncology Center in Opole, Clinical Oncology Department and Day Hospitalization Unit

Opole, Poland

No email / No phone

Status: Recruiting

LUX MED Oncology LLC, Szamocka Hospital, Department of Clinical Oncology/Chemotherapy

Warsaw, Poland

No email / No phone

Status: Recruiting

Maria Sklodowska-Curie - National Research Institute of Oncology

Warsaw, Poland

No email / No phone

Status: Recruiting

Maria Sklodowska-Curie Institute of Oncology, Branch in Krakow

Krakow, Poland

No email / No phone

Status: Recruiting

Medical Clinic "Komed"

Konin, Poland

No email / No phone

Status: Recruiting

Polish Mother's Memorial Hospital-Research Institute

Lodz, Poland

No email / No phone

Status: Recruiting

Prof. Franciszek Lukaszczyk Oncology Center in Bydgoszcz, Chemotherapy Outpatient Clinic

Bydgoszcz, Poland

No email / No phone

Status: Recruiting

Provincial Specialist Hospital in Wroclaw, Department of Chemotherapy

Wroclaw, Poland

No email / No phone

Status: Recruiting

St. John Paul 2nd Mazovian Provincial Hospital in Siedlce Limited Liability Company, Siedlce Oncology Centre

Siedlce, Poland

No email / No phone

Status: Recruiting

West Pomeranian Oncology Center

Szczecin, Poland

No email / No phone

Status: Recruiting

Onco Clinic Consult S.A.

Craiova, Romania

No email / No phone

Status: Recruiting

Oncology Center "Sf. Nectarie"

Craiova, Romania

No email / No phone

Status: Recruiting

Prof. Dr. Alexandru Trestioreanu Institute of Oncology

Bucharest, Romania

No email / No phone

Status: Recruiting

S.C. Oncopremium-Team SRL

Baia Mare, Romania

No email / No phone

Status: Recruiting

S.C. Topmed Medical Center SRL

Târgu Mureş, Romania

No email / No phone

Status: Recruiting

Curie Oncology

Singapore, Singapore

No email / No phone

Status: Recruiting

ICON SOC Farrer Park Medical Clinic

Singapore, Singapore

No email / No phone

Status: Recruiting

OncoCare Cancer Centre

Singapore, Singapore

No email / No phone

Status: Recruiting

Raffles Hospital

Singapore, Singapore

No email / No phone

Status: Recruiting

Tan Tock Seng Hospital

Singapore, Singapore

No email / No phone

Status: Recruiting

Asan Medical Center

Seoul, South Korea

No email / No phone

Status: Recruiting

Gangnam Severance Hospital

Soeul, South Korea

No email / No phone

Status: Recruiting

Korea University Anam Hospital

Soeul, South Korea

No email / No phone

Status: Recruiting

Samsung Medical Center

Soeul, South Korea

No email / No phone

Status: Recruiting

Severance Hospital, Yonsei University Health System

Soeul, South Korea

No email / No phone

Status: Recruiting

Ulsan University Hospital

Ulsan, South Korea

No email / No phone

Status: Recruiting

Caceres Hospital Complex - San Pedro de Alcantara General Hospital

Cáceres, Spain

No email / No phone

Status: Recruiting

Catalan Institute of Oncology, Hospital Duran i Reynals

Barcelona, Spain

No email / No phone

Status: Recruiting

Hospital Ruber Internacional

Madrid, Spain

No email / No phone

Status: Recruiting

Infanta Cristina Hospital

Badajoz, Spain

No email / No phone

Status: Recruiting

University Clinical Hospital Virgen de la Arrixaca, Department of Oncology

Murcia, Spain

No email / No phone

Status: Recruiting

University Hospital Complex of Santiago (CHUS), Department of Oncology

Santiago de Compostela, Spain

No email / No phone

Status: Recruiting

University Hospital Foundation Jimenez Diaz

Madrid, Spain

No email / No phone

Status: Recruiting

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan

No email / No phone

Status: Recruiting

National Cheng Kung University Hospital

Tainan City, Taiwan

No email / No phone

Status: Recruiting

National Taiwan University Hospital

Taipei, Taiwan

No email / No phone

Status: Recruiting

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

No email / No phone

Status: Recruiting

CARTI Cancer Center

Little Rock, Arkansas, 72205, United States

No email / No phone

Status: Recruiting

St. Bernards Medical Center

Jonesboro, Arkansas, 72401, United States

No email / No phone

Status: Recruiting

Cancer and Blood Specialty Clinic

Los Alamitos, California, 90720, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Medical Center - Vallejo

Vallejo, California, 94589, United States

No email / No phone

Status: Recruiting

Pacific Cancer Care

Monterey, California, 93940, United States

No email / No phone

Status: Recruiting

Redlands Hematology Oncology

Redlands, California, 92373, United States

No email / No phone

Status: Recruiting

Torrance Memorial Physician Network - Cancer Care

Torrance, California, 90505, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology-Santa Monica

Santa Monica, California, 90904, United States

No email / No phone

Status: Recruiting

University of California, Irvine Medical Center

Orange, California, 92868, United States

No email / No phone

Status: Recruiting

Yale Cancer Center - New Haven

New Haven, Connecticut, 06520-8028, United States

No email / No phone

Status: Recruiting

Cancer Specialists of North Florida - Jacksonville

Jacksonville, Florida, 32256, United States

No email / No phone

Status: Recruiting

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

South Broward Hospital District d/b/a Memorial Healthcare System

Hollywood, Florida, 33021, United States

No email / No phone

Status: Recruiting

John D. Archbold Memorial Hospital

Thomasville, Georgia, 31792, United States

No email / No phone

Status: Recruiting

Illinois Cancer Specialists - Arlington Heights

Arlington Heights, Illinois, 60005, United States

No email / No phone

Status: Recruiting

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, 46845, United States

No email / No phone

Status: Recruiting

Mercy Health - Paducah

Paducah, Kentucky, 42003, United States

No email / No phone

Status: Recruiting

University of Kentucky Medical Center

Lexington, Kentucky, 40536-0293, United States

No email / No phone

Status: Recruiting

American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817-7847, United States

No email / No phone

Status: Recruiting

Maryland Oncology Hematology, P.A. - Rockville

Rockville, Maryland, 20850, United States

No email / No phone

Status: Recruiting

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Dana Farber Cancer Institute

Boston, Massachusetts, 02215-5450, United States

No email / No phone

Status: Recruiting

Henry Ford Hospital

Detroit, Michigan, 48202, United States

No email / No phone

Status: Recruiting

Nebraska Hematology - Oncology, P.C.

Lincoln, Nebraska, 68506, United States

No email / No phone

Status: Recruiting

Oncology Hematology West PC dba Nebraska Cancer Specialists

Omaha, Nebraska, 68130, United States

No email / No phone

Status: Recruiting

Coleman, Pasmantier & Decter, MDs

New York, New York, 10021-5302, United States

No email / No phone

Status: Recruiting

Hematology/Oncology Associates of Central New York

Syracuse, New York, 13057, United States

No email / No phone

Status: Recruiting

Montefiore Medical Center

The Bronx, New York, 10467, United States

No email / No phone

Status: Recruiting

New York Oncology Hematology, P.C. - Albany

Albany, New York, 12206, United States

No email / No phone

Status: Recruiting

Queens Hospital Cancer Center

Jamaica, New York, 11432, United States

No email / No phone

Status: Recruiting

Weill Cornell Medicine/New York-Presbyterian Hospital

New York, New York, 10021, United States

No email / No phone

Status: Recruiting

White Plains Hospital

White Plains, New York, 10601, United States

No email / No phone

Status: Recruiting

Cone Health Cancer Center at Alamance Regional, Hematology/Oncology

Greensboro, North Carolina, 27403, United States

No email / No phone

Status: Recruiting

Southeast Regional Cancer Center

Lumberton, North Carolina, 28359, United States

No email / No phone

Status: Recruiting

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106-1716, United States

No email / No phone

Status: Recruiting

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States

No email / No phone

Status: Recruiting

Oregon Oncology Specialists

Salem, Oregon, 97301, United States

No email / No phone

Status: Recruiting

Alliance Cancer Specialists PC

Horsham, Pennsylvania, 19044, United States

No email / No phone

Status: Recruiting

Sanford Gynecologic Oncology Clinic

Sioux Falls, South Dakota, 57104, United States

No email / No phone

Status: Recruiting

Brooke Army Medical Center

Houston, Texas, 78234, United States

No email / No phone

Status: Recruiting

Oncology Consultants

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

Texas Oncology - Austin

Austin, Texas, 78745, United States

No email / No phone

Status: Recruiting

Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States

No email / No phone

Status: Recruiting

Texas Oncology - Gulf Coast

Sugar Land, Texas, 77479, United States

No email / No phone

Status: Recruiting

Texas Oncology - Tyler

Tyler, Texas, 75702, United States

No email / No phone

Status: Recruiting

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

William Beaumont Army Medical Center

El Paso, Texas, 79920, United States

No email / No phone

Status: Recruiting

Bon Secours St. Francis Medical Oncology Center

Midlothian, Virginia, 23114, United States

No email / No phone

Status: Recruiting

Fort Belvoir Community Hospital

Fort Belvoir, Virginia, 22060, United States

No email / No phone

Status: Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Roanoke

Roanoke, Virginia, 24014, United States

No email / No phone

Status: Recruiting

VCU Massey Cancer Center

Richmond, Virginia, 23219, United States

No email / No phone

Status: Recruiting

Virginia Oncology Associates - Newport News

Newport News, Virginia, 23502, United States

No email / No phone

Status: Recruiting

Fred Hutchinson Cancer Center

Seattle, Washington, 98109-1023, United States

No email / No phone

Status: Recruiting

Northwest Medical Specialties, PLLC - Tacoma

Tacoma, Washington, 98405, United States

No email / No phone

Status: Recruiting

Pergamino Clinic

Buenos Aires, Argentina

No email / No phone

Status: Not yet recruiting

BC Cancer - Vancouver, Medical Oncology

Vancouver, British Columbia, Canada

No email / No phone

Status: Not yet recruiting

Hospital Notre-Dame

Montreal, Quebec, Canada

No email / No phone

Status: Not yet recruiting

Christian Medical College, Department of Medical Oncology

Vellore, India

No email / No phone

Status: Not yet recruiting

HCG Cancer Centre

Bangalore, India

No email / No phone

Status: Not yet recruiting

Postgraduate Institute of Medical Education and Research (PGIMER)

Chandigarh, India

No email / No phone

Status: Not yet recruiting

China Medical University Hospital

Taichung, Taiwan

No email / No phone

Status: Not yet recruiting

Taipei Medical University - Shuang Ho Hospital

New Taipei City, Taiwan

No email / No phone

Status: Not yet recruiting

Taipei Veterans General Hospital

Taipei, Taiwan

No email / No phone

Status: Not yet recruiting

Guy's Hospital

London, United Kingdom

No email / No phone

Status: Not yet recruiting

Nottingham City Hospital

Nottingham, United Kingdom

No email / No phone

Status: Not yet recruiting

Royal Marsden Hospital - London, Department of Medical Oncology

London, United Kingdom

No email / No phone

Status: Not yet recruiting

Royal United Hospital, Department of Oncology/Hematology

Bath, United Kingdom

No email / No phone

Status: Not yet recruiting

The Christie NHS Foundation Trust

Manchester, United Kingdom

No email / No phone

Status: Not yet recruiting

Velindre Cancer Centre

Cardiff, United Kingdom

No email / No phone

Status: Not yet recruiting

University of Rochester Medical Center

Rochester, New York, 14642, United States

No email / No phone

Status: Not yet recruiting

Peninsula & South Eastern Hematology and Oncology Group (PSEHOG)

Frankston, Australia

No email / No phone

Status: Completed

Tata Medical Center

Kolkata, India

No email / No phone

Status: Completed

Tata Memorial Hospital

Navi Mumbai, India

No email / No phone

Status: Completed

Inbiomedyc

Querétaro, Mexico

No email / No phone

Status: Completed

Prof. Dr. Ion Chiricuta Institute of Oncology

Cluj-Napoca, Romania

No email / No phone

Status: Completed

Arizona Oncology (US Oncology/McKesson) - Goodyear

Goodyear, Arizona, 85395, United States

No email / No phone

Status: Completed

Kaiser Permanente South Bay Medical Center

Harbor City, California, 90710, United States

No email / No phone

Status: Completed

PIH Health Hospital Whittier

Whittier, California, 90602-1006, United States

No email / No phone

Status: Completed

Pacific Cancer Medical Center Inc

Anaheim, California, 92801, United States

No email / No phone

Status: Completed

Ventura County Hematology Oncology Specialists

Oxnard, California, 93030, United States

No email / No phone

Status: Completed

Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A.

Winter Haven, Florida, 33881, United States

No email / No phone

Status: Completed

University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

No email / No phone

Status: Completed

Northwest Cancer Specialists, PC - Tigard

Tigard, Oregon, 97223, United States

No email / No phone

Status: Completed

Cancer Care Associates of York

York, Pennsylvania, 17403, United States

No email / No phone

Status: Completed

Consultants In Medical Oncology and Hematology, P.C.

Broomall, Pennsylvania, 19008, United States

No email / No phone

Status: Completed

Texas Oncology - McKinney

McKinney, Texas, 75071, United States

No email / No phone

Status: Completed

Texas Oncology P.A. - Dallas

Dallas, Texas, 75230, United States

No email / No phone

Status: Completed

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Gedatolisib (PKI-587, PF-05212384)

Overview

Mechanism of action

Efficacy

Safety

Additional notes

Further reading

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (217)

9 of July Sanatorium

Alexander Fleming Institute

Buenos Aires British Hospital

CEDIT Diagnostic and treatment center

CENIT Foundation

CER San Juan

Center for Medical Education and Clinical Research (CEMIC)

Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)

Cordoba Oncology Institute (IONC)

Fleischer Medical Center

Medical Center Austral

Rosario's Oncology Institute and Medical Specialities (IOR)

Adelaide Oncology & Haematology

Hollywood Private Hospital, Breast Cancer Research Centre

Icon Cancer Centre- Southport

Mater Hospital Brisbane, Mater Cancer Care Centre

St Vincent's Hospital (Melbourne) Ltd

Sydney Adventist Hospital

The Queen Elizabeth Hospital

Hospital Hietzing, Department of Gynecology

Medical University Vienna, Department of Gynecology and Obstetrics

Order Hospital Linz Ltd. - Hospital of Sisters of Mercy, Department of Internal Medicine I

Salzburg Regional Hospital, Department of Internal Medicine III

University Hospital Graz, Department of Gynecology and Obstetrics

University Hospital Innsbruck - Tyrolean Hospital, Department of Gynaecology and Obstetrics

University Hospital St. Poelten, Department of Internal Medicine I

AZ Groeninge

Centre Hospitalier Peltzer-la-Tourelle

Charleroi Grand Hospital (GHDC)

Citadelle Regional Hospital Center

Saint Luc University Hospital

UCL Mont-Godinne University Hospitals

University Hospital Antwerp (UZA)

University Hospitals Leuven, Campus Gasthuisberg

VITAZ

Bahia Oncology Center

D'OR Institute

Hospital A.C.Camargo

Juiz de Fora Eurolatino Research Center

ONCOSITE - Clinical Research Center in Oncology

Pronutrir

Oncology Treatment Center

MHAT for Women's Health "Nadezhda"

Multiprofile Hospital for Active Treatment "Serdika", Sofia

Multiprofile Hospital for Active Treatment - Uni Hospital, Panagyurishte

Specialized Hospital for Active Treatment in Oncology, Clinic of Medicial Oncology (Chemotherapy)

University Multiprofile Hospital for Active Treatment "Sveta Marina"

CIUSSS du Saguenay Lac St-Jean

Maisonneuve-Rosemont Hospital

Thomayer University Hospital, Clinic of Oncology

University Hospital Bulovka, Institute of Radiation Oncology

University Hospital Motol, Clinic of Oncology

University Hospital Olomouc, Clinic of Oncology

Bergonie Institute

CHU La Timone - La Timone Children's Hospital

Francois Baclesse Center

Gustave Roussy

La Roche-sur-Yon Hospital

Saint Anne Clinic

University Hospital Center of Poitiers

Caritas Klinikum

Helios Clinic Wuppertal

Hospital Bayreuth

Hospital Suedstadt Rostock

Private Practice with Focus on Oncology